BR112022010702A2 - Macrociclos para uso no tratamento de doenças - Google Patents

Macrociclos para uso no tratamento de doenças

Info

Publication number
BR112022010702A2
BR112022010702A2 BR112022010702A BR112022010702A BR112022010702A2 BR 112022010702 A2 BR112022010702 A2 BR 112022010702A2 BR 112022010702 A BR112022010702 A BR 112022010702A BR 112022010702 A BR112022010702 A BR 112022010702A BR 112022010702 A2 BR112022010702 A2 BR 112022010702A2
Authority
BR
Brazil
Prior art keywords
macrocycles
diseases
treatment
present disclosure
methods
Prior art date
Application number
BR112022010702A
Other languages
English (en)
Inventor
W Rogers Evan
Ung Jane
Nguyen Vivian
Zhai Dayong
Deng Wei
J Cui Jingrong
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76091584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022010702(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of BR112022010702A2 publication Critical patent/BR112022010702A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

MACROCICLOS PARA USO NO TRATAMENTO DE DOENÇAS. A presente divulgação refere-se a certos derivados macrocíclicos de diaril quirais, composições farmacêuticas que os contêm e métodos para usá-los para tratar câncer.
BR112022010702A 2019-12-03 2020-12-02 Macrociclos para uso no tratamento de doenças BR112022010702A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943098P 2019-12-03 2019-12-03
US202063015937P 2020-04-27 2020-04-27
PCT/US2020/062859 WO2021113339A1 (en) 2019-12-03 2020-12-02 Macrocycles for use in treating disease

Publications (1)

Publication Number Publication Date
BR112022010702A2 true BR112022010702A2 (pt) 2022-10-04

Family

ID=76091584

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010702A BR112022010702A2 (pt) 2019-12-03 2020-12-02 Macrociclos para uso no tratamento de doenças

Country Status (14)

Country Link
US (3) US11634433B2 (pt)
EP (1) EP4069700A4 (pt)
JP (1) JP2023504523A (pt)
KR (1) KR20220133869A (pt)
CN (1) CN114929710B (pt)
AU (1) AU2020395136A1 (pt)
BR (1) BR112022010702A2 (pt)
CA (1) CA3163735A1 (pt)
CO (1) CO2022008817A2 (pt)
IL (1) IL293458A (pt)
MX (1) MX2022006853A (pt)
PE (1) PE20221485A1 (pt)
TW (1) TW202134249A (pt)
WO (1) WO2021113339A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929710B (zh) 2019-12-03 2024-03-29 特普医药公司 用于治疗疾病的巨环
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物
WO2024017380A1 (zh) * 2022-07-22 2024-01-25 南京明德新药研发有限公司 含三并环的大环类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526330T1 (de) * 2000-12-28 2011-10-15 Ono Pharmaceutical Co Heterotrizyklische verbindungen als antagonisten des crf-rezeptors
US8211891B2 (en) * 2008-04-30 2012-07-03 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
CA2849999A1 (en) 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US9714258B2 (en) * 2014-01-24 2017-07-25 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
JP6871903B2 (ja) * 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
PL3728271T3 (pl) * 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
US20210087206A1 (en) * 2017-12-19 2021-03-25 Turning Point Therapeutics, Inc. Macrocyclic kinase inhibitors and their use
TW201932472A (zh) * 2018-01-30 2019-08-16 大陸商上海吉倍生物技術有限公司 具有大環分子結構的化合物及其用途
CN114929710B (zh) 2019-12-03 2024-03-29 特普医药公司 用于治疗疾病的巨环

Also Published As

Publication number Publication date
PE20221485A1 (es) 2022-09-26
US11142533B2 (en) 2021-10-12
AU2020395136A1 (en) 2022-07-07
US20230322806A1 (en) 2023-10-12
US11634433B2 (en) 2023-04-25
CO2022008817A2 (es) 2022-09-20
TW202134249A (zh) 2021-09-16
CA3163735A1 (en) 2021-06-10
MX2022006853A (es) 2022-09-19
IL293458A (en) 2022-07-01
WO2021113339A1 (en) 2021-06-10
JP2023504523A (ja) 2023-02-03
CN114929710B (zh) 2024-03-29
CN114929710A (zh) 2022-08-19
KR20220133869A (ko) 2022-10-05
US20210163499A1 (en) 2021-06-03
EP4069700A4 (en) 2023-05-17
US20210246145A1 (en) 2021-08-12
EP4069700A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
BR112022010702A2 (pt) Macrociclos para uso no tratamento de doenças
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112017004589A2 (pt) composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
MX2019003134A (es) Terapia de combinacion.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2020001727A (es) Terapia de combinacion.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
AU2018271862A1 (en) Combination therapy
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
BR112022000713A2 (pt) Imidazopirimidinas como inibidores de eed e o uso das mesmas
ECSP22043592A (es) Inhibidores de egfr alost?ricos y m?todos de uso de los mismos
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
CL2023000061A1 (es) Macrociclos y su uso
BR112017026191A2 (pt) compostos tricíclicos e seu uso como inibidores de fosfodiesterase
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático